CA
NZ
UK
AU
IND
US
…
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD. The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia. As of May 23, 2024, Landos Biopharma, Inc. operates as a subsidiary of AbbVie Inc.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -39.28M | -38.42M | -30.14M | -13.47M | -6.04M |
| Net income | -37.99M | -38.23M | -30.14M | -13.93M | -6.04M |
| Selling general administrative | 14.88M | 15.25M | 5.34M | 1.48M | 1.14M |
| Gross profit | - | 18.00M | - | - | - |
| Reconciled depreciation | 0.58M | 0.20M | 0.14M | 0.10M | 0.08M |
| Ebit | -41.14M | -39.01M | -30.68M | -13.29M | -5.93M |
| Ebitda | -40.56M | -38.82M | -30.08M | -13.03M | -5.85M |
| Depreciation and amortization | 0.58M | 0.20M | 0.59M | 0.26M | 0.08M |
| Operating income | -40.56M | -38.82M | -30.68M | -13.29M | -7.94M |
| Other operating expenses | 40.56M | 56.82M | 30.68M | 13.29M | 7.94M |
| Interest expense | -0.58M | 0.41M | 0.46M | 0.30M | 0.00M |
| Interest income | 1.26M | 0.41M | 0.46M | - | - |
| Net interest income | 1.26M | 0.41M | 0.46M | -0.30M | -0.00M |
| Income tax expense | -1.28M | -0.20M | -0.08M | 0.46M | 1.90M |
| Total revenue | 0.00M | 18.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 40.56M | 56.82M | 30.68M | 13.29M | 7.94M |
| Total other income expense net | 1.28M | 0.39M | 0.53M | -0.18M | 1.90M |
| Net income from continuing ops | -39.28M | -38.42M | -30.14M | -13.47M | -6.04M |
| Net income applicable to common shares | - | -38.42M | -30.14M | -13.47M | -6.04M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 38.04M | 45.25M | 92.88M | 30.33M | 50.48M |
| Other current assets | 0.49M | 0.85M | 1.27M | 0.20M | 0.14M |
| Total liab | 6.25M | 6.12M | 16.61M | 84.35M | 76.06M |
| Total stockholder equity | 31.79M | 39.13M | 76.27M | -54.02M | -25.58M |
| Deferred long term liab | - | - | - | - | 0.01M |
| Other current liab | 4.87M | 2.69M | 3.70M | 2.43M | 0.98M |
| Common stock | 0.03M | 0.40M | 0.40M | 0.07M | 0.06M |
| Capital stock | 0.03M | 0.40M | 0.40M | 0.07M | 0.06M |
| Retained earnings | -155.36M | -133.43M | -94.15M | -55.73M | -25.59M |
| Other liab | - | - | - | 0.28M | - |
| Other assets | - | - | 0.03M | - | 0.01M |
| Cash | 37.55M | 36.64M | 8.30M | 2.42M | 9.81M |
| Total current liabilities | 6.25M | 6.12M | 16.61M | 11.03M | 3.03M |
| Net debt | -37.55M | -36.64M | -8.30M | -2.42M | -9.81M |
| Other stockholder equity | 187.12M | 172.21M | 77.36M | -71.40M | 0.02M |
| Property plant equipment | - | - | 0.71M | 0.44M | 0.36M |
| Total current assets | 38.04M | 45.25M | 92.15M | 29.89M | 50.11M |
| Net tangible assets | - | - | 76.27M | -54.02M | -25.58M |
| Short term investments | 0.00M | 7.76M | 82.58M | 25.72M | 40.16M |
| Net receivables | - | - | - | 0.15M | 0.00M |
| Inventory | - | - | - | 1.40M | - |
| Accounts payable | 1.38M | 3.44M | 12.91M | 8.61M | 2.05M |
| Accumulated other comprehensive income | - | -0.06M | -0.23M | 0.01M | -0.08M |
| Common stock total equity | - | - | - | 0.07M | 0.06M |
| Non currrent assets other | - | - | 0.03M | 25.72M | 0.01M |
| Non current assets total | 0.00M | 0.00M | 0.73M | 0.44M | 0.37M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 74.06M | -58.27M | 14.31M | -40.17M | -40.17M |
| Change to liabilities | - | 4.26M | 6.51M | 0.41M | 1.00M |
| Total cashflows from investing activities | - | -58.71M | 14.13M | -40.33M | -0.04M |
| Net borrowings | - | - | - | 8.00M | 8.00M |
| Total cash from financing activities | 0.00M | 91.61M | 1.52M | 59.65M | 5.00M |
| Change to operating activities | - | 1.63M | -0.64M | 2.86M | -2.30M |
| Net income | -39.28M | -38.42M | -30.14M | -13.47M | -6.04M |
| Change in cash | 28.34M | 5.89M | -7.39M | 9.45M | -1.94M |
| Begin period cash flow | 8.30M | 2.42M | 9.81M | 0.36M | 2.30M |
| End period cash flow | 36.64M | 8.30M | 2.42M | 9.81M | 0.36M |
| Total cash from operating activities | -45.77M | -27.06M | -22.96M | -9.87M | -6.90M |
| Issuance of capital stock | 0.00M | 93.00M | 0.00M | 51.67M | 5.00M |
| Depreciation | 0.58M | 0.20M | 0.14M | 0.10M | 0.08M |
| Other cashflows from financing activities | 74.06M | -1.39M | 1.52M | -40.33M | 5.00M |
| Change to netincome | - | 5.27M | 1.17M | 0.21M | 0.37M |
| Capital expenditures | 0.01M | 0.44M | 0.18M | 0.16M | 0.04M |
| Change in working capital | -10.07M | 5.89M | 5.87M | 3.28M | -1.30M |
| Stock based compensation | 1.97M | 4.12M | 0.83M | - | - |
| Other non cash items | 1.03M | 1.16M | 0.05M | 0.21M | 0.37M |
| Free cash flow | -45.78M | -27.50M | -23.14M | -10.03M | -6.94M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
-0.54 1.32% |
40.55 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.77 0.29% |
956.64 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD. The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia. As of May 23, 2024, Landos Biopharma, Inc. operates as a subsidiary of AbbVie Inc.
| Name | Title | Year Born |
|---|---|---|
| Mr. Timothy M. Mayleben M.B.A. | Principal Financial Officer & Director | 1961 |
| Dr. Josep Bassaganya-Riera DVM, Ph.D. | Advisor | 1975 |
| Mr. Gregory Oakes | Pres, CEO & Director | 1968 |
| Mr. Patrick Truesdell | Principal Accounting Officer | 1981 |
| Dr. Fabio Cataldi M.D. | Chief Medical Officer | NA |
| Mr. Gregory Oakes | President, CEO & Director | 1968 |
| Dr. Fabio Cataldi M.D. | Executive VP & Chief Medical Officer | 1967 |
| Ms. Jennifer Creel | Interim Chief Financial Officer | 1971 |
| Ms. Rebecca Mosig Ph.D. | Vice President of Corporate Development | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...